The Biochemistry of Metastasis

Advances in Clinical Chemistry

Volumn 32, Issue C, 1996, Pages 135-166

  Duffy, M J ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOCRINE MOTILITY FACTOR; CELL ADHESION MOLECULE; CYTOKINE; MIGRATION STIMULATING FACTOR; PROTEINASE; STEROID RECEPTOR; TUMOR MARKER; TUMOR PROTEIN;

HUMAN; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); ONCOGENE; PHYSIOLOGY; REVIEW; SUPPRESSOR GENE;

AUTOCRINE MOTILITY FACTOR; CELL ADHESION MOLECULES; CYTOKINES; ENDOPEPTIDASES; GENES, SUPPRESSOR; HUMANS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENES; RECEPTORS, STEROID; TUMOR MARKERS, BIOLOGICAL;

EID: 0030339567     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2423(08)60427-8     Document Type: Article

References (137)

1. Alvarez O.A., Carmichael D.F., and DeClerck Y.A. Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. J. Natl. Cancer Inst. 82 (1990) 589-595
2. 0 breast carcinoma. Am. J. Pathol. 18 (1994) 158-166
3. Axelrod J.H., Reich R., and Miskin R. Expression of human recombinant plasminogen activator enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells. Mol. Cell. Biol. 9 (1989) 2133-2141
4. Aznavoorian S., Murphy A.N., Stetler-Stevenson W.G., and Liotta L.A. Molecular aspects of tumor cell invasion and metastasis. Cancer (Philadelphia) 71 (1993) 1368-1383
5. Baici A., Gyger-Marazzi M., and Strauli P. Extracellular cysteine proteinase and collagenase activities as a consequence of tumor-host interaction in the rabbit V2 carcinoma. Invasion Metastasis 4 (1984) 13-27
6. Baker M.S., Bleakley P., Woodrow G.C., and Doe W.F. Inhibition of cancer cell urokinase by its specific inhibitor PAI-1 and subsequent effects on extracellular matrix degradation. Cancer Res. 50 (1990) 4676-4684
7. Barnes D.M., Lammie G.A., Millis R.R., Gullick W.L., Allen D.S., and Altman D.G. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Br. J. Cancer 58 (1988) 448-452
8. Benton L.D., Khan M., and Greco R.S. Integrins, adhesion molecules and surgical research. Surgery (St. Louis) 177 (1993) 311-327
9. Berchuck A., Kamel A., Whitaker R., Kerns B., Olt G., Kinney R., Soper J.T., Dodge R., Clarke-Pearson P., Markes P., McKenzie S., Yin S., and Bast Jr. R.C. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50 (1990) 4087-4091
10. Berg E.L., McEvoy L., Berlin C., Bargatze R., and Butcher E.C. L-selectin-mediated lymphocyte rolling on MAdCAM-1. Nature (London) 366 (1993) 695-698
11. Birch M., Mitchell S., and Hart I.R. Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44. Cancer Res. 65 (1991) 6160-6167
12. Blamey R.W., Bishop H.M., Blake J., Doyle P.J., Elston C., Haybrittle J.L., Nicholson R.I., and Griffiths K. Relationship between primary breast tumor receptor status and patient survival. Cancer (Philadelphia) 46 (1980) 2765-2769
13. Blood C.H., and Zetter B.P. Tumor interactions with the vasculature: Angiogenesis and tumor metastasis. Biochim. Biophys. Acta 1032 (1990) 89-118
14. Bourhis J., DeVathaire F., Wilson G.D., Hartman O., Terrier-Lacombe M.J., Boccon-Gibod L., McNally N.J., Lemerle J., Riou G., and Benard J. Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. Cancer Res. 51 (1991) 33-36
15. r 52,000 cathepsin D secreted by breast cancer cells. Cancer Res. 48 (1988) 3688-3692
16. Cajot J.F., Schleuning W.D., Medcalf R.L., Bamat J., Tetuz J., Libermann L., and Sordat B. Mouse L-cells expressing human prourokinase-type plasminogen activator: Effects on extracellular matrix degradation and invasion. J. Cell. Biol. 109 (1989) 915-925
17. Cajot J.F., Bamat J., Bergonzelli G.E., Kruithof E., Medcalf R.L., Tetuz J., and Sordat B. Plasminogen activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc. Natl. Acad. Sci. U.S.A. 50 (1990) 4676-4684
18. Carmeliet P., Schoonjans L., Kieckens L., Ream B., Degen J., Bronson R., De Vos R., van den Oord J.J., Collen D., and Mulligan R.C. Physiological consequence of loss of plasminogen activator gene function in mice. Nature (London) 358 (1994) 419-424
19. Chackal-Roy R.M., Niemeyer C., More M., and Zetter B.R. Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow. J. Clin. Invest. 84 (1989) 43-50
20. Chan B., Matsuura N., Takada Y., Zetter B.R., and Helmer M.E. In vitro andin vivo consequences of VLA-2 expression on rhabdomyosarcoma cells. Science 251 (1991) 1600-1602
21. Contesso G., Jotti G.S., and Bonadonna G. Tumor grade as a prognostic factor in primary breast cancer. Eur. J. Cancer Clin. Oncol. 25 (1989) 403-409
22. DeClerck Y.A., Yean T.D., Chan D., Shimada H., and Lansley K.E. Inhibition of tumor invasion of smooth muscle cell layers by recombinant human metalloproteinase inhibitor. Cancer Res. 51 (1991) 2151-2157
23. Denekamp J., and Hill S. Angiogenic attack as a therapeutic strategy for cancer. Radiother. Oncol. 20 Supp. 1 (1991) 103-112
24. Duffy M.J., O'Grady P., Devaney D., O'Siorain L., Fennelly J.J., and Lijnen H.R. Urokinase-plasminogen activator, a marker for aggressive breast cancers, preliminary report. Cancer (Philadelphia) 62 (1988) 531-533
25. Duffy M.J., Reilly D., O'Sullivan C., O'Higgins N., Fennelly J.J., and Andreasen P. Urokinase plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res. 50 (1990) 6827-6829
26. Duffy M.J. Biochemical markers as prognostic indices in breast cancer. Clin. Chem. (Winston-Salem, NC) 36 (1990) 188-191
27. Duffy M.J. Role of proteolytic enzymes in cancer invasion and metastasis. Clin. Exp. Metastasis 10 (1992) 145-155
28. Duffy M.J. Urokinase plasminogen activator and malignancy. Fibrinolysis 7 (1993) 295-302
29. Duffy M.J. Cellular oncogenes and suppressor genes as prognostic markers in cancer. Clin. Biochem. 26 (1993) 439-447
30. Duffy M.J., Reilly D., McDermott E., O'Higgins N., Fennelly J.J., and Andreasen P.A. Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer (Philadelphia) 74 (1994) 2276-2280
31. Dumler I.T., Petri T., and Schleuning W.D. Interaction of urokinase-type plasminogen activator (uPA) with its cellular receptor (uPAR) induces phosphorylation on tyrosine of a 38 kDa protein. FEBS Lett. 322 (1993) 37-40
32. East J.A., and Hart I.R. CD44 and its role in tumour progression and metastasis. Eur. J. Cancer 29A (1993) 1921-1922
33. Eekhout Y., and Vaes G. Further studies on the activation of procollagenase, the latest precursor of bone collagenase: Effects of lysosomal cathepsin B, plasmin and kallikrein and spontaneous activation. Biochem. J. 36 (1977) 1555-1563
34. Ewing J. A Treatise on Tumors (1928), Saunders, Philadelphia
35. Fett J.W., Strydom D.J., Lob R.R., Alderman E.M., Bethune J.L., Riordan J.F., and Vallee B.L. Isolation and characterization of angiogenin, an angiogenic protein from human carcinomas cells. Biochemistry 24 (1985) 5480-5486
36. 125l-5-iododeoxyuridine. J. Natl. Cancer Inst. (U.S.) 45 (1970) 773-782
37. Fidler I.J. Selection of successive tumour lines for metastasis. Nature (London) New Biol. 242 (1973) 148-149
38. Fidler I.J., and Nicolson G.L. Organ selectivity for survival and growth of B16 melanoma variant tumor lines. J. Natl. Cancer Inst. (U.S.) 57 (1976) 1199-1201
39. Fidler I.J. Critical factors in the biology of human cancer metastasis: Twenty-eighth G. H. A. Clowes Memorial Award Lecture. Cancer Res. 50 (1990) 6130-6138
40. Foekens J.S., Schmitt M., van Putten W., Peters H.A., Bontenbal M., Janicke F., and Klijn J. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res. 52 (1992) 6101-6105
41. Folkman J., and Shing Y. Angiogenesis. J. Biol. Chem. 267 (1992) 10931-10934
42. Fotsis T., Zhang T., Pepper M.S., Adlercreutz H., Montesano R., Nawroth P.P., and Schwergerer L. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature (London) 368 (1994) 237-239
43. Garbisa S., Pozzatti R., Muschel R., Saffiotti U., Ballin M., and Goldfarb R. Secretion of type IV collagenolytic proteases and metastatic phenotype: Induction by transfection with c-Ha-ras but not c-Ha-ras plus Ad2-Ela. Cancer Res. 47 (1987) 1523-1528
44. Garcia M., Derocq D., Pujol P., and Rochefort H. Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. Oncogene 5 (1990) 1809-1814
45. Gherardi E. Growth factors and cell movement. Eur. J. Cancer 27 (1991) 403-405
46. Gold L.L., Schwimmer R., and Quigley J.B. Human plasma fibronectin as a substrate for human urokinase. Biochem. J. 262 (1989) 529-534
47. Grondahl-Hansen J., Christensen I., Rosenquist C., Brunner N., Mouridsen H.T., Dano K., and Blichert-Toft M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 53 (1993) 2513-2521
48. Gullick W.J., Love S.B., Wright C., Barnes D.M., Gusterson B., Harris A.L., and Altman D.G. C-erbB-2 protein overexpression in breast cancer is a risk factor with involved and uninvolved lymph nodes. Br. J. Cancer 63 (1991) 434-438
49. Gunthert U., Hofmann M., Rudy W., Reber S., Zoller M., Haussman I., Matzku S., Wenzel A., Ponta H., and Herrlich P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell (Cambridge, MA) 65 (1991) 13-24
50. Gyetko M., Todd II R.F., Wilkinson I.C., and Sotrin B.G. The urokinase receptor is required for human monocyte chemotaxis in vitro. J. Clin. Invest. 93 (1994) 1380-1387
51. Hahnel R., Woodings T., and Vivian A.B. Prognostic value of estrogen receptors in primary breast cancer. Cancer (Philadelphia) 44 (1979) 671-675
52. Hamdy F.C., Fadlon E.J., Cottam D., Lawry J., Thurrell W., Silcocks P.B., Anderson J.B., and Rees R.C. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br. J. Cancer 69 (1994) 177-182
53. Harris C.C., and Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med. 329 (1993) 1318-1327
54. Hart I.R. "Seed and soil" revisited: Mechanisms of site-specific metastasis. Cancer Met. Rev. 1 (1982) 5-16
55. Hearing V.J., Law L., Corti A., Appella E., and Blasi F. Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer (Philadelphia) 48 (1988) 1270-1278
56. Henry J.A., McCarthy A.L., Angus B., Westley B.R., May F., Nicholson S., Cairns J., and Harris A.L. Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. Cancer (Philadelphia) 65 (1990) 265-271
57. Henson D.E. The histological grading of neoplasms. Arch. Pathol. Lab. Med. 112 (1988) 1091-1096
58. Horst E., Meijer C., Radaszkiewicz T., Ossekoppele G., Van Krieken J., and Pals S.T. Adhesion molecules in the prognosis of diffuse large cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CDIIa/18) and ICAM-1 (CD54). Leukaemia 4 (1990) 595-599
59. Howat J.M., Harris M., Swindell R., and Barnes D.M. The effect of estrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast. Br. J. Cancer 51 (1985) 263-270
60. Hoyhtya M., Hujanen E., and Turpeenniemi-Hajanen T. Modulation of type IV collagenase and invasive behaviour of metastatic melanoma (A2058) cells in vitro by monoclonal antibodies to type IV collagenase. Intl. J. Cancer 46 (1990) 282-286
61. Isola J., Weitz S., Visakorpi T., Holli K., Shea R., Khalbaz N., and Kallioniemi O.-P. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in auxillary node-negative breast cancer. J. Clin. Oncol. 11 (1993) 36-43
62. Janicke F., Schmitt M., Hafter R., Holrieder A., Babić R., Ulm K., Gossner W., and Graeff H. Urokinase-type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4 (1990) 69-78
63. Janicke F., Schmitt M., Pache L., Ulm K., Harbeck N., Hoffer H., and Graeff H. Urokinase plasminogen activator (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res. Treat. 24 (1993) 195-208
64. Jessup J.M., and Thomas P.C. Carcinoembryonic antigen: Function in metastasis by human colorectal carcinoma. Cancer Metastasis Rev. 8 (1989) 263-280
65. Kellner B., and Sugar J. Morphological factors accompanying growth and invasion. In: Wissler R.W., Dao T.L., and Wood S. (Eds). Endogenous factors influencing host-tumour balance (1967), University of Chicago Press, Chicago, IL 239-251
66. Keren Z., and LeGrue S.J. Identification of cell surface cathepsin B-like activity on murine melanomas and fibrosarcomas: Modulation by butanol extraction. Cancer Res. 48 (1988) 1416-1421
67. Kern J.A., Schwartz D.A., Nordberg J.E., Weiner D.B., Greene M.I., Torney L., and Robinson R.A. P185 neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res. 50 (1990) 5184-5191
68. Khokha R., and Denhardt D.T. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: A review of their role in tumorigenesis and tissue invasion. Invasion Metastasis 9 (1989) 391-405
69. Kihana T., Tsuda H., Teshima S., Nomoto K., Tsugane S., Sonoda T., Matsuura S., and Hirohashi S. Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix. Cancer (Philadelphia) 73 (1994) 148-153
70. Kinsey D.L. An experimental study of preferential metastasis. Cancer (Philadelphia) 13 (1960) 674-676
71. Kirchheimer J.C., Wojta J., Christ G., and Binder B.R. Proliferation of a human epidermal tumor cell line stimulated by urokinase. FASEB J. 1 (1987) 125-128
72. Kirchheimer J.C., Wojta J., Christ G., and Binder B.R. Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 5424-5428
73. Knight W.A., Livingston R.B., Gregory E.J., and McGuire W.L. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res. 37 (1977) 3667-3671
74. Kobayashi H., Schmitt M., Goretzki L., Chuchowolski N., Calvete J., Karamer M., Gunzler W.A., Janicke F., and Graeff H. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-uPA). J. Biol. Chem. 266 (1991) 5147-5152
75. Kodama Y., and Tanaka T. Effect of urokinase on growth and metastasis of rabbit V2 carcinoma. Gann 69 (1978) 9-15
76. Koivunen E., Huhtala M.L., and Stenman U.H. Human ovarian tumor-associated trypsin. J. Biol. Chem. 264 (1989) 14095-14099
77. Kossakouska A.E., Urbanski S.J., Huchcroft S.A., and Edwards R.R. Relationship between clinical aggressiveness of large cell immunoblastic lymphomas and expression of 92 kDa gelatinase (type IV collagenase) and tissue inhibitor of metalloproteinase-1 (TIMP-1). Oncol. Res. 4 (1992) 233-240
78. Kotzin B.L., and Strober S. Role of spleen in the growth of a murine B cell leukemia. Science 208 (1980) 59-61
79. Kristensen P., Pyke C., Lund L.R., Andreasen P.A., and Dano K. Plasminogen activator inhibitor type-1 in Lewis lung carcinoma. Histochemistry 93 (1990) 559-566
80. Lasky L.A. Selections: Interpreters of cell-specific carbohydrate information during inflammation. Science 258 (1992) 964-969
81. Liotta L.A. Principles of molecular cell biology of cancer: Cancer metastasis. In: DeVita Jr. V., Hellman S., and Rosenberg S. (Eds). Cancer: Principles and Practice of Oncology. 4th ed. (1993), Lippincott, Philadelphia 134-149
82. Lyons R.M., Keski-Oja J., and Moses H.L. Proteolytic activation of latent transforming growth factor-beta from fibroblast conditioned medium. J. Cell Biol. 106 (1988) 1659-1665
83. Mackay C.R., and Imhof B.A. Cell adhesion in the immune system. Immunol. Today 14 (1993) 99-102
84. Mareel M., Bracke M., Van Roy F., and Vakaet L. Expression of E-cadherin in embryogenetic ingression and cancer invasion. Int. J. Dev. Biol. 37 (1993) 227-235
85. Mayer B., Jauch K., Gunthert U., Figdor C., Schildberg F., Funke I., and Johnson J. De-novo expression of CD44 and survival in gastric cancer. Lancet 342 (1993) 1019-1022
86. McDonnell S., and Matrisian L.M. Stromelysin in tumor progression and metastasis. Cancer Metastasis Rev. 9 (1990) 305-319
87. Moertel G., Fleming T.R., MacDonald J.S., Haller D.G., Laurie J.A., and Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. J. Am. Med. Assoc. 270 (1993) 943-947
88. Moller L.B. Structure and function of urokinase receptor. Blood Coagulation Fibrinolysis 4 (1993) 293-303
89. Mulcahy H.E., Duffy M.J., Gibbons D., McCarthy P., Parfrey N.A., O'Donoghue D.P., and Sheahan K. Urokinase plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet. 344 (1994) 583-584
90. Nekarda H., Siewert J., Schmitt M., and Ulm K. Tumor-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer. Lancet 343 (1994) 117
91. Neri A., Bohoslawec O., Anderson T.D., and Tokes Z.A. Differential release of active proteinase inhibitors by 2 rat mammary adenocarcinoma variants possessing different metastatic potentials. Cancer Res. 51 (1991) 1318-1325
92. Nicolson G.L. Cancer metastasis, organ colonization and cell surface properties of malignant cells. Biochim. Biophys. Acta 695 (1982) 113-176
93. Nicolson G.L. Paracrine and autocrine growth mechanisms in tumor metastasis to specific sites with particular emphasis on brain and lung metastasis. Cancer Metastasis Rev. 12 (1993) 325-343
94. Nierodjik M.L., Plotkin A., Kajuno F., and Karpatkin S. Thrombin stimulates tumorplatelet adhesionin vitro and metastasis in vivo. J. Clin. Invest. 87 (1991) 229-236
95. Nishimura Y., Kawabata T., and Kato K. Identification of latent procathepsin B and L in microsomal lumen. Arch. Biochem. Biophys. 261 (1988) 64-71
96. Nowell P.C. How many human cancer genes?. J. Natl. Cancer Inst. 83 (1991) 1061-1064
97. Ossowski L., and Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell (Cambridge, MA) 35 (1983) 611-619
98. Ossowski L., Russo-Payne H., and Wilson E.L. Inhibition of urokinase-type plasminogen activator by antibodies: The effect on dissemination of a human tumor in the nude mouse model. Cancer Res. 51 (1991) 274-281
99. Pagano M., Dalet-Fumeron V., and Engler R. The glycosylation state of the precursors of the cathepsin-like proteinase from human malignant ascitic fluid: Possible implication in the secretory pathways of these proenzymes. Cancer Lett. 45 (1989) 13-19
100. Paget S. Distribution of secondary growths in cancer of the breast. Lancet 1 (1889) 571-573
101. Poste G., and Fidler I.J. The pathogenesis of cancer metastasis. Nature (London) 283 (1980) 139-146
102. Proctor J.W. Rat sarcoma model supports both "soil seed" and "mechanical" theories of metastatic spread. Br. J. Cancer 34 (1976) 651-654
103. Pyke C., Kristensen P., Ralfkiaer E., Grondahl-Hansen J., Eriksen K., Blasi F., and Dano K. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am. J. Pathol. 138 (1991) 1059-1067
104. Qian K., Bajkouski A., Steiner D.F., Chan S.J., and Frankfater A. Expression of 5 cathepsins in murine melanomas of varying metastatic potential and normal tissue. Cancer Res. 49 (1989) 4870-4875
105. Reilly D., Christensen L., Duch M., Nolan N., Duffy M.J., and Andreasen P.A. Type-1 plasminogen activator inhibitor in human breast carcinomas. Int. J. Cancer 50 (1992) 208-214
106. Reith A., and Rucklidge G. Invasion of brain tissue by primary glioma: Evidence for involvement of urokinase-type plasminogen activator as an activator of type IV collagenase. Biochem. Biophys. Res. Commun. 186 (1992) 348-354
107. Rochefort H. Cathepsin D in breast cancer: A tissue marker associated with metastasis. Eur. J. Cancer 28A (1992) 1783-1791
108. Roos E., and Dingemaus K.P. Mechanisms of metastasis. Biochim. Biophys. Acta. 560 (1979) 135-166
109. Rougon G., Durbec P., and Figarella-Branger D. Adhesion molecules in cancer. The Cancer Journal 5 (1992) 137-141
110. Rozhin J., Gomez A.P., Zigler G.H., Nelson K.K., Chang Y.S., Fong D., Honn K.V., and Sloane B.F. Cathepsin B to cysteine proteinase inhibitor balance in metastatic cell subpopulations isolated from murine tumors. Cancer Res. 50 (1990) 6278-6284
111. Ruoslahti E. Control of cell motility and tumour invasion by extracellular matrix interactions. Br. J. Cancer 66 (1990) 239-242
112. Saksela O. Plasminogen activation and regulation of pericellular proteolysis. Biochim. Biophys. Acta 823 (1985) 35-65
113. Schmitt M., Janicke F., and Graeff H. Tumor-associated proteases. Fibrinolysis 6 Suppl. 4 (1992) 3-26
114. Seeger R.C., Brodeur G.M., Sather H., Dalton A., Sregel S.E., Wong K.Y., and Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N. Engl. J. Med. 313 (1985) 111-116
115. Shimizu Y., and Shaw S. Mucins in the mainstream. Nature (London) 336 (1993) 630-631
116. Skriver L., Larsson L., Kielberg V., Nielsen L.S., Andresen P.B., Kristensen P., and Dano K. Immunocytochemical localisation of urokinase type plasminogen activator in Lewis lung carcinoma. J. Cell. Biol. 99 (1984) 753-758
117. D.J. Slamon G.M. Clark S.G. Wong W.J. Levin A. Ullrich W.L. McGuire Human breast cancer: Correlation of relapse with amplification of the HER-2/neu oncogene. Science 235 177-182
118. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Uclove J., Ullrich A., and Press M. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
119. Sloane B.F., Moin K., Krepela E., and Rozhin J. Cathepsin B and its endogenous inhibitors: The role in tumor malignancy. Cancer Metastasis Rev. 9 (1990) 333-352
120. Spyratos F., Brouillet J.P., Defrenne A., Hacene K., Rouesse J., Maudelonde T., Brunet M., Andrieu C., Desplaces A., and Rochefort H. Cathepsin D: An independent prognostic factor for metastasis of breast cancer. Lancet 2 (1989) 1115-1118
121. Spyratos F., Martin P.-M., Hacene K., Romain S., Andrieu C., Ferrero-Pous M., Deytieux S., Le Doussal V., Tubiana-Hurlin M., and Brunet M. Multiparametric prognostic evaluation of biological factors in primary breast cancers. J. Natl. Cancer Inst. 84 (1992) 1266-1272
122. Su L.K., Vogelstein B., and Kinzler K.W. Association of the APC tumor suppressor protein with catenins. Science 262 (1993) 1734-1737
123. Tanaka N., Ogawa H., Tanaka K., Kingo M., and Kohga S. Effects of tranexamic acid and urokinase on hematogenous metastases of Lewis lung carcinoma in mice. Invasion Metastasis 1 (1991) 149-157
124. Tandon A.K., Clarke G.M., Chamness G.C., Chirgwin J., and McGuire W.L. Cathepsin D and prognosis in breast cancer. N. Engl. J. Med. 322 (1990) 297-302
125. Thorpe S.A., Christensen I.J., Rasmussen B.B., and Rose C. Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancer. Eur. J. Cancer 29A (1993) 971-977
126. Tryggvason K., Hoyhtya M., and Salo T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim. Biophys. Acta 907 (1987) 191-207
127. Underhill C. CD44: The hyaluronan receptor. J. Cell Sci. 103 (1992) 293-298
128. Vignon F., Capony F., Chambon M., Freiss G., Garcia M., and Rochefort H. Autocrine growth stimulation on the MCF7 breast cancer cells by the estrogen-regulated 52K protein. Endocrinology 118 (1986) 1537-1545
129. Visscher D.W., Sloane B.F., Sameni M., Babiarz J., Jacobson J., and Crissman J.D. Clinicopathologic significance of cathepsin B immunostaining in transitional neoplasia. Mod. Pathol. 7 (1994) 76-81
130. Weinberg R.A. Tumor suppressor genes. Science 254 (1991) 1138-1145
131. Wielenga V., Heider K.H., Johan G., Offerhaus A., Adolf G., Van den Berg F., Ponta H., Herrlich P., and Pals S. Expression of CD 44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res. 53 (1993) 4754-4756
132. Wood Jr. S. Pathogenesis of metastasis formation observed in the rabbit ear chamber. Arch. Pathol. 66 (1958) 550-558
133. Yamada K.M., Kennedy D.W., Yamada S.S., Grahnick H., Chen W.T., and Akiyama S.K. Monoclonal antibodies and synthetic peptides as inhibitors of human tumor cell migration. Cancer Res. 50 (1990) 4485-4496
134. Yonemura Y., Ninomiya I., Ohoyama S., Fushide S., Kosaka T., Miiva K., Miyazaki I., Endou Y., Tanaka M., and Sasaki T. Expression of c-erbB-2 oncoprotein in gastric carcinoma. Cancer (Philadelphia) 67 (1991) 2914-2918
135. Yu H., and Schultz R.M. Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res. 50 (1990) 7623-7633
136. Zetter B.R. The cellular basis of site-specific metastasis. N. Engl. J. Med. 322 (1990) 605-612
137. Zou Z., Anisowicz A., Hendrix M., Thor A., Neveu M., Sheng S., Rafidi K., Seftor E., and Sager R. Maspin: A serpin with tumor-suppressing activity in human mammary epithelial cells. Science 263 (1994) 526-529